Table 1.
The comparison of clinical and imaging feature, 30-day outcomes between the SAMMPRIS trial and the present study.
| The SAMMPRIS trial | The present study | |
|---|---|---|
| No. of patients | 224 | 71 |
| Average age | 61.0 ± 10.7 | 58.9 ± 8.2 |
| Male/female | 56.7%/43.3% | 76.1/23.9% |
| No. of treated lesions | 224 | 71 |
| Severe stenosis (70–99%) | 100% | 100% |
| LESION LOCATION | ||
| ICA | 20.1% | 12.7% |
| MCA (M1 segment) | 41.1% | 23.9% |
| VA | 17.0% | 26.8% |
| BA | 21.9% | 36.6% |
| QUALIFYING EVENT | ||
| TIA | 36.6% | 26.8% |
| Stroke | 63.4% | 73.2% |
| Mean length of stenosis (mm) | 6.7 | 7.6 |
| MEAN STENOSIS DEGREE | ||
| Pretreatment | 79.7% | 84.2% |
| Posttreatment | 27.0% | 16.9% |
| Technical success | 92.0% | 100% |
| COMPLICATIONS | ||
| Ischemic stroke within 30 d | 23 (10.2%) | 0% |
| Hemorrhagic stroke within 30 d | 10 (4.5%) | 0% |
| Death within 30 d | 5 (2.2%) | 0% |
| Overall stroke or death within 30 d | 33 (14.7%) | 0% |